Phaseline

Targets › CYP19A1

CYP19A1 (Aromatase): drug programs, companies and trials

32 programs from 30 companies in 139 trials: 62 Phase 2, 31 Phase 3, 26 Phase 4, 20 Phase 1; Oncology, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.

A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively. Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta…. (UniProt, P11511)

Open in Phaseline: the race on CYP19A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
Gangnam Severance HospitalAromatase inhibitors
Aromatase inhibition
CYP19A1Phase 4Breast CancerJan 2031
National Cancer Institute (NCI)Anastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Breast Ductal Carcinoma In Situ; Breast AdenocarcinomaJan 2027
National Cancer Institute (NCI)Exemestane
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Breast Ductal Carcinoma In Situ; Anatomic Stage III Breast Cancer AJCC v8; Breast AdenocarcinomaJan 2027
Alliance for Clinical Trials in Oncologyanastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Estrogen Receptor-positive Breast CancerApr 2027
Georgios PapadakisAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Klinefelter SyndromeApr 2027
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Breast CancerJun 2028
University of VirginiaAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Breast Cancer FemaleJun 2029
Azienda Ospedaliero-Universitaria Careggianastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Breast CancerMar 2030
NRG OncologyAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Stage I Breast CancerApr 2031
NRG OncologyAromatase Inhibitor (AI)
Aromatase inhibitor - reduces estrogen production
CYP19A1Phase 3Breast CancerJan 2032
Institute of Cancer Research, United KingdomAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 3Breast CancerApr 2034
ReproNovo ApsLeflutrozole, Dose 1
Aromatase inhibitor
CYP19A1Phase 2Semen QualityNov 2026
Hebei Medical University Fourth HospitalAromatase inhibitor
Aromatase inhibitor (estrogen synthesis inhibitor)
CYP19A1Phase 2Breast CancerDec 2026
Washington University School of MedicineAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Breast CancerJan 2027
Jose Pablo LeoneAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Male Breast CancerApr 2027
UNC Lineberger Comprehensive Cancer Centeranastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Breast CancerApr 2027
Dartmouth-Hitchcock Medical CenterAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Breast CancerAug 2027
Centre Leon BerardAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Low Grade Endometrial Stromal SarcomaJan 2028
Wake Forest University Health SciencesAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Female Breast CarcinomaJun 2028
Medical College of WisconsinAromatase inhibitors
Aromatase inhibitor
CYP19A1Phase 2Breast CancerSep 2028
University of California, IrvineAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Breast CancerDec 2028
University of MiamiAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Breast CancerJul 2029
Memorial Sloan Kettering Cancer Centeranastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Breast CancerMar 2030
UNICANCERAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Breast CancerNov 2030
Institut Cancerologie de l'OuestAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Ductal Carcinoma in SituAug 2033
International Cancer Research Group, United Arab EmiratesAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer–
Shayna Showalter, MDanastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 2Breast Cancer Female–
Martin Blomberg JensenLeflutrozole
Aromatase inhibitor
CYP19A1Phase 1Infertility Due to AzoospermiaMay 2027
Icahn School of Medicine at Mount SinaiAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 1Breast NeoplasmsJul 2027
Rovi Pharmaceuticals LaboratoriesLetrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 1Hormone Receptor Positive Early Breast Cancer; Polycystic Ovary Syndrome; Abortion in First Trimester; Miscarriage in First Trimester …May 2028
Northwestern UniversityAnastrozole
Cytochrome P450 19A1 inhibitor
CYP19A1Phase 1Inguinal Hernia UnilateralJul 2028

Conditions

Breast Cancer (29) Breast Cancer Female (4) Breast Ductal Carcinoma In Situ (3) Breast Adenocarcinoma (3) Nicotine Dependence (3) Endometrial Cancer (3) Psoriasis Vulgaris (2) Cytomegalovirus (CMV) (2) Ectopic Pregnancy (2) Stage I Breast Cancer (2) Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer (2) Endometrial Neoplasms (2)

Modalities

small molecule (22), protein or peptide (6), mixed (4)

Companies

National Cancer Institute (NCI) (2) NRG Oncology (2) Shayna Showalter, MD (1) Icahn School of Medicine at Mount Sinai (1) IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy (1) Medical College of Wisconsin (1) Institute of Cancer Research, United Kingdom (1) Institut Cancerologie de l'Ouest (1) Wake Forest University Health Sciences (1) Dartmouth-Hitchcock Medical Center (1) Azienda Ospedaliero-Universitaria Careggi (1) Memorial Sloan Kettering Cancer Center (1) University of California, San Francisco (1) University of California, Irvine (1) University of Miami (1) Hebei Medical University Fourth Hospital (1) University of Virginia (1) Washington University School of Medicine (1) Jose Pablo Leone (1) ReproNovo Aps (1)

Related targets

ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1) CHRM3 (1) CHRM2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.